Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies
Latest Information Update: 20 Apr 2022
At a glance
- Drugs LMN-Cdiff01 (Primary)
- Indications Clostridium difficile infections
- Focus First in man; Pharmacokinetics
- Sponsors Lumen Bioscience
- 18 Apr 2022 According to a Lumen Bioscience media release, the company plans to publish full study results in a peer-reviewed journal after complete data analysis.
- 18 Apr 2022 Primary endpoint has been met. (Presence or absence of capsules and/or transit markers in ostomy fluid by visual observation), according to a Lumen Bioscience media release.
- 01 Mar 2022 Status changed from recruiting to completed.